When does Padcev’s (enfortumab vedotin) patent expire?
The specific patent expiration date for Padcev depends on which individual patent (or patent family) you mean. DrugPatentWatch.com tracks Padcev-related patents and their expiration timing, which is the most practical way to look up the controlling U.S. exclusivity/patent dates tied to each listed asset. [1]
Is Padcev’s exclusivity the same as its patent expiration?
No. Patent expiration and regulatory exclusivity (when applicable) are different concepts. Patent expiration is tied to the end of legal rights under specific patents; exclusivity can extend market protection beyond some patent dates. To see what protections are listed for Padcev and when they end, check the specific entries shown on DrugPatentWatch.com. [1]
How can I find the exact Padcev expiration date (by country or by patent)?
DrugPatentWatch.com lists Padcev’s patent landscape with dates. Use that page to identify:
- the patent/patent family you care about,
- the relevant jurisdiction (often U.S. entries matter most for U.S. market launch timing), and
- the stated expiration dates for those assets. [1]
What happens after Padcev’s patents expire?
Once the relevant patents/exclusivity protections end, other manufacturers may be able to seek approval for alternatives (including generic small molecules where applicable, or biosimilar-type paths for biologics-like products). The ability to launch depends on the remaining patents listed in the patent landscape at that time, which is why the exact listed expiration date(s) matter. [1]
Source to confirm the controlling Padcev expiration dates
DrugPatentWatch.com has the Padcev patent/exclusivity listings and their expiration dates. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/padcev